BR112015023145A2 - polipeptídeos contendo fc aglicosilados - Google Patents
polipeptídeos contendo fc aglicosiladosInfo
- Publication number
- BR112015023145A2 BR112015023145A2 BR112015023145A BR112015023145A BR112015023145A2 BR 112015023145 A2 BR112015023145 A2 BR 112015023145A2 BR 112015023145 A BR112015023145 A BR 112015023145A BR 112015023145 A BR112015023145 A BR 112015023145A BR 112015023145 A2 BR112015023145 A2 BR 112015023145A2
- Authority
- BR
- Brazil
- Prior art keywords
- 2rby
- glycosylated
- kinase
- containing polypeptides
- agglucosylated
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 101100366888 Dictyostelium discoideum dstA gene Proteins 0.000 abstract 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 230000004068 intracellular signaling Effects 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 102000027257 transmembrane receptors Human genes 0.000 abstract 1
- 108091008578 transmembrane receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
Abstract
resumo polipeptídeos contendo fc aglicosilados são fornecidas aqui moléculas fc de igg1 humana variante desprovidas de ou com função efetora altamente reduzida e alta estabilidade, apesar de desprovidas de glicosilação em n297. também são fornecidos aqui peptídeos ligantes que são glicosilados quando expressos em células de mamífero. il-2 liga três subunidades de receptor transmembrana: il-2r- e il-2ry que juntas ativam eventos de sinalização intracelular mediante ligação de il-2 e cd-25 (il-2ra) que serve para estabilizar a interação entre il-2 e il-2rby. os sinais distribuídos por il-2rby incluem aqueles da pi3-cinase, ras-mao-cinase e vias stat5.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784669P | 2013-03-14 | 2013-03-14 | |
| US61/784,669 | 2013-03-14 | ||
| PCT/US2014/028913 WO2014153063A1 (en) | 2013-03-14 | 2014-03-14 | AGLYCOSYLATED Fc-CONTAINING POLYPEPTIDES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015023145A2 true BR112015023145A2 (pt) | 2017-11-21 |
| BR112015023145B1 BR112015023145B1 (pt) | 2023-09-12 |
Family
ID=
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201591731A1 (ru) | АГЛИКОЗИЛИРОВАННЫЕ Fc-СОДЕРЖАЩИЕ ПОЛИПЕПТИДЫ | |
| BR112016014156A8 (pt) | Moléculas efetoras quiméricas etiquetadas e receptores das mesmas | |
| BR112019014986A8 (pt) | Anticorpo que alveja bcma e uso do mesmo | |
| BR112014017165A8 (pt) | polipeptídeos de fator quimérico viii e seus usos | |
| BR112019001108A2 (pt) | usos de vesículas extracelulares compreendendo uma proteína de fusão tendo capacidade de ligação a fc | |
| BR112015000267A2 (pt) | complexo do fator viii com xten e proteína de fator de von willebrand e usos dos mesmos | |
| MX2017007136A (es) | Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8. | |
| WO2015066551A3 (en) | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof | |
| BR112017006178A2 (pt) | região fc, anticorpos, formulação farmacêutica e usos dos anticorpos | |
| BR112017021696A2 (pt) | muteínas de interleucina-2 para a expansão de células t regulatórias | |
| EA201101660A8 (ru) | Бифункциональные полипептиды | |
| CL2012001853A1 (es) | Formulación farmacéutica que comprende un anticuerpo humano que se une de modo especifico al receptor de interleuquina 6 humana (hil-6r), histidina y un carbohidrato. | |
| BR112013026828A2 (pt) | polipeptídeos de anticorpo que antagonizam cd40 | |
| MX2019009641A (es) | Receptores de la celula t que reconocen mhc de mage-a3 de clase ii-restringida. | |
| BR112015022119A2 (pt) | Polipeptídeo, composto conjugado, composição farmacêutica, ácido nucleico, vetor, células hospedeiras procariótica e eucariótica, método de produção de um polipeptídeo, e, método de tratamento | |
| WO2014074532A3 (en) | Compositions and methods for modulating cell signaling | |
| PE20150650A1 (es) | Polipeptidos que contienen fc con glicosilacion alterada y funcion efectora reducida | |
| ATE475669T1 (de) | Einen modifizierten t-zellen-rezeptor exprimierende zellen | |
| BR112019011065A2 (pt) | métodos para determinação da dosagem de células t car | |
| BR112014026531A2 (pt) | proteínas de ligação de antígeno ligando cd30 humano | |
| BR112016001036A2 (pt) | fusocinas envolvendo citocinas com afinidades de ligação de receptores fortemente reduzida | |
| BR112022011399A2 (pt) | Receptor de antígeno quimérico baseado em lilrb1 | |
| WO2015066379A3 (en) | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide | |
| BR112015019729A2 (pt) | composição inibidora da il-1b e uso da mesma | |
| UY33274A (es) | Proteínas de unión a basigina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2014, OBSERVADAS AS CONDICOES LEGAIS |